Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who carry, or are at high risk of carrying, a specific gene change in the EGFR gene (such as T790M or similar) that was found through a blood or saliva test, including through broader cancer gene panel testing — this includes both the person who was first tested and their family members
- People who carry, or are at high risk of carrying, a gene change in a gene other than EGFR that may be linked to an inherited risk of lung cancer, found through a blood or saliva test — this includes both the person first tested and their family members
- People who have been diagnosed with lung cancer, do not have a known inherited gene change, but have at least one of the following: a close family member (parent, sibling, or child) who has had lung cancer; lung cancer across multiple generations of their family; a personal history of more than one separate lung cancer or other cancer; or lung cancer that appears in multiple areas of the lung — this includes both that person and their family members
- Blood relatives of people in any of the above groups, including those who may be carriers of a relevant gene change or who serve as healthy comparison participants
- People whose genetic information or medical samples were previously collected under a related study at Dana-Farber Cancer Institute, provided their earlier consent allows that information to be shared
- In some cases, information about deceased family members may be included, using medical records, tissue samples, or official records such as death certificates — if medical records or samples are needed, a next-of-kin family member (such as a spouse, child, parent, or sibling) would need to provide consent
- People whose gene change was initially found through inherited (germline) testing but is later found to be limited to certain cells rather than inherited — these people may remain in the study, though the trial site may not ask them to complete ongoing surveys or provide further samples
- People whose gene change results are uncertain in significance may be considered eligible at the lead researcher's discretion (confirm with trial site)
Who may not be able to join:
- People who do not wish to give their consent to participate
- People who are unable to give consent themselves and do not have a nominated healthcare proxy or legal representative to consent on their behalf
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jaclyn LoPiccolo, MD, PhD, Dana-Farber Cancer Institute
Phone: 617-632-6036
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of rare germline EGFR mutations; Prevalence of rare germline non-EGFR mutations; Prevalence of rare pathogenic or likely pathogenic germline variants in familial lung cancers; Prevalence of rare pathogenic or likely pathogenic germline variants in lung cancer patients with multiple primary cancers or multi-focal NSCLC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.